# EDGAR Filing Document

**Accession Number:** 0001571015
**File Stem:** 0001213900-25-092422
**Filing Date:** 2025-9
**Character Count:** 6868
**Document Hash:** 240ea6c1155b9f98b980ca19e59e4b25
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-092422.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001213900-25-092422

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250916

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Zours Wilhelm Konrad Thomas
- **CENTRAL INDEX KEY:** 0001571015

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40943
- **FILM NUMBER:** 251351242

**MAIL ADDRESS:**
- **STREET 1:** ZIEGELHAUSER
- **STREET 2:** LANDSTRASE 1
- **CITY:** HEIDELBERG
- **STATE:** 2M
- **ZIP:** 69120
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biofrontera Inc.
- **CENTRAL INDEX KEY:** 0001858685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473765675
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 781-245-1325

**MAIL ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Zours Wilhelm Konrad Thomas<br><sub>(Last) (First) (Middle)</sub><br>ZIEGELHAUSER LANDSTRASSE 3<br><sub>(Street)</sub><br>HEIDELBERG, 2M 69120<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Biofrontera Inc. [ BFRI ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-09-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 400000 | I | By Biofrontera AG<sup>(1)(2)</sup> |
| Common Stock | 58884 | I | By Deutsche Balaton Aktiengesellschaft<sup>(3)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series D Convertible Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 4831172 | $0.6249 | I | By Biofrontera AG<sup>(1)(2)</sup> |

---

### Footnotes:

(1) The reported shares are held directly by Biofrontera AG. The Reporting Person owns a majority interest in Delphi Unternehmensberatung Aktiengesellschaft, which owns a majority interest in VV Beteiligungen Aktiengesellschaft, which owns a majority interest in Deutsche Balaton Aktiengesellschaft. Collectively, Delphi Unternehmensberatung Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft and Deutsche Balaton Aktiengesellschaft hold approximately 62.2% of the outstanding voting stock of Biofrontera AG.

(2) In addition, the Reporting Person is a member of the management board of VV Beteiligungen Aktiengesellschaft and a management board member of Delphi Unternehmensberatung Aktiengesellschaft. As a result of the above, the Reporting Person may be deemed to beneficially own the shares owned by Biofrontera AG. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

(3) The reported shares are held directly by Deutsche Balaton Aktiengesellschaft. The Reporting Person owns a majority interest in Delphi Unternehmensberatung Aktiengesellschaft, which owns a majority interest in VV Beteiligungen Aktiengesellschaft, which owns a majority interest in Deutsche Balaton Aktiengesellschaft. In addition, the Reporting Person is a member of the management board of VV Beteiligungen Aktiengesellschaft and a management board member of Delphi Unternehmensberatung Aktiengesellschaft. As a result of the above, the Reporting Person may be deemed to beneficially own the shares owned by Deutsche Balaton Aktiengesellschaft. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

(4) The convertible preferred stock is convertible at any time at the holder's option, subject to a limitation that prevents the holder and its affiliates from beneficially owning more than 19.99% of the outstanding common stock upon conversion. The preferred stock has no expiration date.

**Signature:** /s/ Martin Flick, attorney in fact for Wilhelm Konrad Thomas Zours  
**Date:** 2025-09-26

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**